Target-Mediated Disposition Model Describing the Dynamics of IL12 and IFNγ after Administration of a Mifepristone-Inducible Adenoviral Vector for IL-12 Expression in Mice
Journal Title: The AAPS Journal - Year 2013, Vol 15, Issue 1
Abstract
The online version of this article (doi:10.1208/s12248-012-9423-9) contains supplementary material, which is available to authorized users.
Authors and Affiliations
Zinnia Patricia Parra-Guillen, Alvaro Janda, Pilar Alzuguren, Pedro Berraondo, Ruben Hernandez-Alcoceba, Iñaki F. Troconiz
Keywords
Related Articles
- EP ID EP681758
- DOI 10.1208/s12248-012-9423-9
- Views 90
- Downloads 0
Pilot Investigation on Long-Term Subcutaneous Microdialysis: Proof of Principle in Humans
Reliable drug concentration measurements at the target site are increasingly demanded and can be achieved by microdialysis. The aim of this pilot study was to demonstrate the proof of principle of long-term subcutaneous...
Pharmacodynamic modeling of chemotherapeutic effects: Application of a transit compartment model to characterize methotrexate effects in vitro
The time course of chemotherapeutic effect is often delayed relative to the time course of chemotherapeutic exposure. In many cases, this delay is difficult to characterize mathematically through the use of standard phar...
Estimation of Biliary Excretion of Foreign Compounds Using Properties of Molecular Structure
The online version of this article (doi:10.1208/s12248-013-9541-z) contains supplementary material, which is available to authorized users.
Efficacious Intestinal Permeation Enhancement Induced by the Sodium Salt of 10-undecylenic Acid, A Medium Chain Fatty Acid Derivative
The online version of this article (doi:10.1208/s12248-014-9634-3) contains supplementary material, which is available to authorized users.
Model-Based Decision Making in Early Clinical Development: Minimizing the Impact of a Blood Pressure Adverse Event
We describe how modeling and simulation guided program decisions following a randomized placebo-controlled single-rising oral dose first-in-man trial of compound A where an undesired transient blood pressure (BP) elevati...